Volunteers sought for virtual clipboard initiative

 

Several organizations led by the Sullivan Institute for Healthcare Innovation are seeking volunteers for a virtual clipboard initiative designed to facilitate the patient intake process, including automating the collection of critical health insurance and demographic information.

The Sullivan Institute is working in partnership with the Workgroup for Electronic Data Interchange (WEDI), the Healthcare Information and Management Systems Society (HIMSS) and the Medical Group Management Association (MGMA).

The project culminates from recommendations contained in the 2013 WEDI Report, and seeks to leverage smart technologies to enhance the patient experience while improving patient safety. Specifically the groups are looking to build a solution that allows a “clipboard” of demographic, insurance and critical clinical data to be disseminated electronically to the provider.

The goal is to design, launch and measure the Phase 1 pilot solution in 2015, according to a release.

“We are encouraged by the resounding industry response during last month’s launch of this initiative, which included active counsel from more than 40 representatives from major health plans, providers, health IT vendors and government entities,” said Devin Jopp, EdD, president and CEO of WEDI, in a statement. “Now we’re opening the call to action even further, welcoming more industry volunteers to serve as thought leaders and help guide efforts to drive this important initiative.”

Visit the institute’s website.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.